In addition, C5a-C5aR1 could activate neutrophils and mononuclear cells to secret inflammatory factors, which form the hyperinflammatory response, whereas anti-C5aR1 monoclonal antibodies could suppress acute lung injury in patients with severe COVID-19. Here, C5AR1 is linked to COVID-19.